TGFB1 and cholangiocarcinoma: Nevertheless, the latest phase II/III clinical trial (NCT04066491) using a TGF-β inhibitor in combination with chemotherapy failed to meet expectations and has been discontinued,6,7 indicating that there are unknown mechanisms compromising the use of TGF-β as a therapeutical target in CCA.